Publications by authors named "Asim Ali Khan"

7 Publications

  • Page 1 of 1

Effects of co-administration of pharmacopoeia formulations and with CAT-I antitubercular drugs in rats.

J Complement Integr Med 2021 May 10. Epub 2021 May 10.

ICMR-National Institute for Research in Tuberculosis (NIRT), Chennai, Tamil Nadu, India.

Objectives: Tuberculosis continues to be a major public health problem globally, despite incredible advancements in healthcare system. In system of medicine, (QTS) and (AHB) have been traditionally used for tuberculosis like conditions. The study was aimed to investigate the effects of co-administration of QTS and AHB with category I first line antitubercular drugs (CAT-I) on the indices of liver and kidney function in rats.

Methods: QTS and AHB were prepared individually and mixed to achieve final compound pharmacopoeia formulation (UPF). The human equivalent doses for rats were calculated and administered with and without CAT-I. The effects of the formulations on serum indices of kidney and liver function, hematological markers and plasma CAT-I drug levels were estimated at 14th, 60th & 180th days of treatment.

Results: The administration of UPF, CAT-I and UPF + CAT-I altered the levels of aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP) and gamma glutamyltransferase (GGT) and haematological markers. These alterations were within permissible range and randomly distributed among groups during various time points. Administration of CAT-I alone resulted in moderate histopathological changes which were completely abrogated in CAT-I + UPF co-administered animals. The co-administration of UPF with CAT-I improved the plasma peak rifampicin (RIF) levels, without altering the liver and kidney functions.

Conclusions: The co-administration of UPF with ATT improved liver and kidney functions and increased the plasma levels of RIF. These beneficial findings provide a scope to evaluate the pharmacokinetic studies in humans.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1515/jcim-2020-0262DOI Listing
May 2021

Emergence of antimicrobial resistance and magnitude of Unani medicine - scope and challenges.

J Complement Integr Med 2021 Jan 29. Epub 2021 Jan 29.

Central Council for Research in Unani Medicine, Ministry of AYUSH, Govt. of India, New Delhi, India.

Emergence of antimicrobial resistance, with practically all newly developed and even more potent antibiotics like carbapenem and colistin, has become a matter of great public health concern. A number of common diseases of public health importance are becoming harder and sometimes impossible to treat due to increased resistance of pathogens. These alarming threats seek prime attention of scientific community to develop newer antibiotics with long-lasting efficacy, least side effects, and low economic burden. Unani classical texts have enormous citations on different infectious diseases. Many single drugs and compound formulations are in vogue since ages for the treatment of infectious diseases. Use of Afaviya (spices), Mufarrehat (exhilarants), Tiryaqi Advia (drugs with antidote properties) and Sirka (vinegar) is highly advocated in treating various infectious diseases. Though, enormous research activities have been undertaken worldwide to explore and develop newer antibiotics from natural resources, indicating massive magnitude of natural products in treating various infectious diseases, however, the higher plants, still largely seems to be unexplored. Moreover, elaborated and well controlled clinical studies are still lacking to authenticate their clinical significance. Hence, a rigorous, well-designed & well-structured research is highly paramount to ascertain the provision of newer, relatively safe and cost effective natural antibiotics.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1515/jcim-2020-0092DOI Listing
January 2021

Lithotriptic effect of in patients of (Nephrolithiasis) - an open prospective clinical validation trial.

J Complement Integr Med 2020 May 19;18(1):139-146. Epub 2020 May 19.

Central Council for Research in Unani Medicine, New Delhi, Ministry of AYUSH, Govt of India, India.

Background: (Nephrolithiasis) is one of the most common chronic conditions and has been known to the mankind since antiquity. The incidence is increasing globally with geographic, racial and gender variation in its occurrence. Medical management of Nephrolithiasis still poses a considerable challenge for modern medical practice. Unani drugs possessing lithotriptic activity are not only cost effective but also have least side effects. has been used since long for the treatment of (Nephrolithiasis) but no documentary evidence based on scientific parameters as to its safety and efficacy are available.

Objective: To validate the safety and efficacy of in the treatment of .

Methodology: An open prospective clinical trial was carried out on 107 subjects of renal calculi of 3-7 mm diameter diagnosed by Ultrasonogram-KUB (USG-KUB). Subjects were evaluated by clinical history & examination, laboratory investigations followed by USG-KUB for confirmation. The safety was assessed by reporting of adverse events and by pathological and biochemical investigations. Assessment of efficacy was based on improvement observed in VAS score and expulsion/reduction of stone size as detected by USG-KUB.

Results: Substantial reduction (53%) in the size of calculi confirmed by USG-KUB and considerable lowering of VAS score (75%) were observed with the active intervention in majority of the cases.

Conclusion: The trial has revealed that the Unani pharmacopoeal formulation was well tolerated and has the therapeutic potential in the reduction and expulsion of renal calculi.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.1515/jcim-2019-0301DOI Listing
May 2020

Quality Control and Stability Testing of Arq Formulations of Unani Pharmacopeia of India Using HPTLC and GC-MS.

J AOAC Int 2020 Jun;103(3):699-704

Jamia Hamdard, School of Pharmaceutical Education and Research, Bioactive Natural Product Laboratory, Department of Pharmacognosy and Phytochemistry, New Delhi, India 110080.

Background: There is an increasing global demand for traditional medicines because of their efficacy, ease of availability, and few or no side effects. The Unani medicines have long been used in India and abroad for various disorders and diseases. Arqiyat (Arq; distillate) is one of the most widely used Unani formulation prepared by simple distillation from single or combination drugs.

Objective: In the present investigation, an attempt has been made to generate data for quality control and stability testing of Arq formulations of the Unani Pharmacopeia of India that includes only three Arq formulations.

Method: Arq-e-Nana (AeN), Arq-e-Gazar (AeG), and Arq-e-Brinjasif (AeB) were prepared through hydrodistillation. Quality control and stability analysis were performed by using HPTLC and GC-MS.

Results: Dichloromethane extract of AeB showed maximum of 10 bands at different retardation factor values; however, there are 7 bands in AeN as well as in AeG. GC-MS analysis showed presence of 10 metabolites in AeG, 8 in AeN, and 9 in AeB. Stability studies showed that the shelf life of Arq formulations would be enhanced at refrigeration (5 ± 2°C) conditions.

Conclusions: The present study highlights quality control and stability analysis of Arq formulations of Unani Pharmacopeia of India using HPTLC and GC-MS.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.5740/jaoacint.19-0230DOI Listing
June 2020

Evaluation of a classical unani pharmacopeial formulation safoof-e-muhazzil in hyperlipidemia: A randomized, standard controlled clinical study.

J Pharm Bioallied Sci 2014 Jul;6(3):167-79

Department of AYUSH, LRIUM, CCRUM, Hamdard Nagar, New Delhi, India.

Aim Of The Study: The aim of the following study is to evaluate the efficacy and tolerability of a compound Unani formulation in hyperlipidemia on clinical and biochemical parameters.

Materials And Methods: A total of 90 patients with total cholesterol level of 220 mg/dl and above were included. In Group 'A' thirty patients with total cholesterol 243.5 ± 5.294 mg/dl received Unani formulation safoof-e-muhazzil (SM) in its classical powder form 5 g twice daily orally, in Group 'B' thirty patients with total cholesterol 234 ± 3.822 mg/dl received the SM but in compressed tablet form in the same dosage and in Group 'C' 30 patients with total cholesterol 242.7 ± 5.563 mg/dl received atorvastatin 10 mg as a standard control. Follow-up was carried out on second, fourth and 6th week and patients were evaluated on clinical as well as biochemical parameters.

Results: Group A before treatment had mean total cholesterol of 243.5 ± 5.294 mg/dl which decreased significantly after treatment to 225.6 ± 5.953 mg/dl (P < 0.001) with a percentage change of 7.35%. Group B had mean total cholesterol of 234 ± 3.822 mg/dl which was significantly reduced to 212.67 ± 3.94 mg/dl (P < 0.001) post-treatment with a percentage change of 9.11%. Control Group C having mean total cholesterol of 242.7 ± 5.563 mg/dl before treatment was significantly decreased to 178.73 ± 4.669 mg/dl (P < 0.001) post-treatment with a percentage change of 26.3%. Group A had significant relief 20.72% (P < 0.001) in fatigue, 16.09% (P > 0.5) relief in palpitation and 26.17% (P < 0.001) relief in dyspnea post-treatment. Group B fatigue decreased significantly by 18.14% (P < 0.01), palpitation by 22.91% (P < 0.01) and dyspnea by 20.46% (P < 0.01). In Group C a non-significant increase of 2.2% was observed in fatigue post-treatment, palpitation decreased by 10.22% non-significantly and dyspnea decreased significantly by 17.64% (P < 0.001). Results indicate that the test drug safely and effectively ameliorates the clinical condition of patients with hyperlipidemia while decreasing cholesterol level as well.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/0975-7406.130975DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4097930PMC
July 2014

Management of knee osteoarthritis with cupping therapy.

J Adv Pharm Technol Res 2013 Oct;4(4):217-23

Literary Research Institute of Unani Medicine(LRIUM), Jamia Hamdard, New Delhi, India.

The study aimed to evaluate the effect of cupping therapy at a clinical setting for knee osteoarthritis. A randomized, controlled clinical trial was conducted. Cupping was performed on 0-6(th) day; 9-11(th) day and 14(th) day, i.e., 11 sittings follow-up to determine longer term carryover of treatment effects utilizing both objective and subjective assessment. The assessment was performed before and after treatment spreading over a period of 15 days. The results of this study shows significant and better results in the overall management of knee osteoarthritis, particularly in relieving pain, edema, stiffness and disability. The efficacy of treatment with cupping therapy in relieving signs and symptoms of knee osteoarthritis is comparable to that of acetaminophen 650 mg thrice a day orally, in terms of analgesia, anti-inflammatory and resolution of edema with minimal and temporary side-effects like echymosis and blister formation while as control drug has greater side-effects particularly on upper gastrointestinal tract. It is recommended that further studies are conducted with a larger study samples and of longer duration.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/2231-4040.121417DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853699PMC
October 2013

Efficacy of a classical antiobesity Unani pharmacopial formulation (Safoof-e-Muhazzil) in systolic and diastolic blood pressure: A randomized, open-labeled, controlled clinical study.

J Adv Pharm Technol Res 2013 Oct;4(4):190-7

LRIUM, CCRUM, Department of AYUSH, Jamia Hamdard, New Delhi, India.

The aim of this study is to evaluate the efficacy of a Unani formulation in hypertension. A total of 90 patients with total cholesterol level of more than 220 mg/dl with associated conditions were included in this study. A total of 30 patients having a mean systolic blood pressure (BP) of 133.86 mmHg comprising Group A received Unani formulation Safoof-e-Muhazzil (SM) in its classical powder form in the dose of 5 g twice a day orally. Group B comprising of 30 patients with a mean systolic BP of 133.13 mmHg received same drug, but in compressed tablet form in the same dosage, whereas, 30 patients comprising Group C with a mean systolic BP of 129.45 mmHg, received Atorvastatin 10 mg as a standard control. Patients were evaluated on each follow-up at 2(nd), 4(th) and 6(th) week. The mean systolic BP in Group A and B before treatment was 133.86 ± 3.028 mmHg and 133.13 ± 2.852 mmHg, which significantly decreased to 119.33 ± 1.922 mmHg (P < 0.001) and 119 ± 1.760 mmHg (P < 0.001) respectively. In the control Group C before treatment BP was 129.45 ± 2.499 mmHg and after treatment it significantly decreased to 124.34 ± 1.794 mmHg (P < 0.01). The percentage change after treatment was 10.85%, 10.61% and 3.94% respectively in each group. Mean diastolic BP in Group A and B before treatment was 85.06 ± 2.11 mmHg and 84.56 ± 1.5 mmHg, which significantly decreased to 79.06 ± 1.56 mmHg (P < 0.001) and 79.96 ± 1.15 mmHg (P < 0.001) respectively, BP before treatment in Group C was 83.23 ± 1.588 mmHg, which was decreased to 124.34 ± 1.794 mmHg (P < 0.01). The study results indicate that the test drug was quite effective in reducing both systolic as well as diastolic BP.
View Article and Find Full Text PDF

Download full-text PDF

Source
http://dx.doi.org/10.4103/2231-4040.121413DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3853695PMC
October 2013